CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Monte Rosa Therapeutics (NASDAQ:GLUE – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for CRISPR Therapeutics and Monte Rosa Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CRISPR Therapeutics | 1 | 7 | 9 | 2 | 2.63 |
| Monte Rosa Therapeutics | 1 | 2 | 8 | 1 | 2.75 |
CRISPR Therapeutics currently has a consensus price target of $65.75, suggesting a potential upside of 34.16%. Monte Rosa Therapeutics has a consensus price target of $26.67, suggesting a potential upside of 154.45%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than CRISPR Therapeutics.
Insider and Institutional Ownership
69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares CRISPR Therapeutics and Monte Rosa Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CRISPR Therapeutics | $11.00 million | 430.81 | -$581.60 million | ($4.76) | -10.30 |
| Monte Rosa Therapeutics | $123.67 million | 7.23 | -$38.63 million | ($1.76) | -5.95 |
Monte Rosa Therapeutics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares CRISPR Therapeutics and Monte Rosa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CRISPR Therapeutics | -3,368.72% | -24.39% | -18.25% |
| Monte Rosa Therapeutics | -560.85% | -43.31% | -27.59% |
Volatility & Risk
CRISPR Therapeutics has a beta of 1.76, meaning that its stock price is 76% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500.
Summary
Monte Rosa Therapeutics beats CRISPR Therapeutics on 9 of the 15 factors compared between the two stocks.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
About Monte Rosa Therapeutics
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
